RALEIGH, N.C., June 9, 2022 /PRNewswire/ — Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partner program designed to move clinical AI/ML innovation to the front lines of healthcare. The Collaborative will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.

“Imaging biomarkers to better evaluate and predict treatment response for complex diseases.” Company Presentation Theater 2 Wednesday, June 15, 2022 4:00 pm- 4:15 pm ( PDT)

Find out more about AIQ Solutions technologies at kiosk IH22!

AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy.

Stop by our booth #923

Immuno-Oncology 360 2022 March 16-18, 2022 New York Marriott Brooklyn Bridge

AIQ Solutions will be attending J.P. Morgan 39th Annual Healthcare Conference from January 11th through January 15th, 2021 in a virtual format. Request a meeting to learn more about AIQ Solutions and our treatment response quantification and prediction technology.

AIQ Solutions will be attending Immuno-Oncology 360° from February 23rd through 26th, 2021 in a virtual format. Request a meeting to learn more about AIQ Solutions, and our treatment response quantification and prediction technology.

AIQ Solutions will be attending ASCO Genitourinary Cancers Symposium from February 11th through 13th, 2021 in a virtual format. Request a meeting to learn more about AIQ Solutions, and our treatment response quantification and prediction technology.